Rivkin Anna 4

What Happened

• Anna Rivkin, Chief Business Officer of Foghorn Therapeutics (FHTX), received a grant of derivative securities covering 165,000 shares on January 30, 2026. The reported per-share price for the derivative is $5.71, giving a notional value of $942,150. This filing reports an award/grant (code A) — a grant of rights to acquire shares rather than an immediate open‑market purchase or sale.

Key Details

• Transaction date: 2026-01-30; Filing date: 2026-02-02 (appears timely).
• Instrument: Derivative award/option covering 165,000 shares with a $5.71 per‑share strike/price; total reported value $942,150.
• Vesting (footnote): 25% of the underlying shares vest on January 30, 2027, then 6.25% of the underlying shares vest on the first day of each calendar quarter thereafter.
• Shares owned after transaction: Not specified in the filing.
• Transaction code: A = Award/Grant (this is a grant of rights to acquire shares, not an immediate purchase or sale).

Context

• This is a compensation-related grant (derivative/option) that vests over time. It should not be read as an immediate market purchase or sale; such awards are common for executives and align incentives with long‑term performance. The filing does not show any immediate exercise or sale of the underlying shares.